Li Kang Biomedical Co Ltd (6242) — Cash Flow Quality Index
Li Kang Biomedical Co Ltd (6242) has a Cash Flow Quality Index of -0.30x as of March 2026. Operating cash flow of NT$-3.17 Million is below net income of NT$10.62 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore how well can Li Kang Biomedical Co Ltd service its debt to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Li Kang Biomedical Co Ltd Cash Flow Quality Index (2002–2025)
Historical Cash Flow Quality Index for Li Kang Biomedical Co Ltd across 12 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see how efficiently does Li Kang Biomedical Co Ltd generate cash.
Annual Cash Flow Quality Index for Li Kang Biomedical Co Ltd (2002–2025)
Year-by-year earnings quality comparison for Li Kang Biomedical Co Ltd.
| Year | Quality Index | Operating CF (TWD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 1.10x | NT$92.15 Million | NT$83.82 Million | ▲ +29.5% |
| 2024 | 0.85x | NT$65.38 Million | NT$77.02 Million | ▲ +22.1% |
| 2023 | 0.70x | NT$96.74 Million | NT$139.14 Million | ▼ -37.7% |
| 2022 | 1.12x | NT$157.24 Million | NT$140.80 Million | ▲ +17.3% |
| 2021 | 0.95x | NT$60.45 Million | NT$63.48 Million | ▲ +1.4% |
| 2020 | 0.94x | NT$81.67 Million | NT$86.94 Million | ▼ -26.9% |
| 2019 | 1.29x | NT$92.56 Million | NT$72.02 Million | ▼ -6.5% |
| 2018 | 1.38x | NT$105.53 Million | NT$76.74 Million | ▲ +66.3% |
| 2017 | 0.83x | NT$110.61 Million | NT$133.74 Million | ▼ -54.1% |
| 2016 | 1.80x | NT$110.82 Million | NT$61.51 Million | ▲ +49.0% |
| 2015 | 1.21x | NT$63.91 Million | NT$52.85 Million | ▼ -48.7% |
| 2002 | 2.36x | NT$45.87 Million | NT$19.46 Million | — |